Finally, it must be take into account that NRF2 levels can be regulated in a KEAP1-indipendent way by carcinoid tumor-related oncogenes, so their profile should impact and must be monitored to predict a tumor response to pharmacological treatments [67]. The gene discussed is NFE2L2; the disease is carcinoid tumor.